Literature DB >> 27905699

Green light vaporization of the prostate: is it an adult technique?

Aldo Brassetti1, Cosimo DE Nunzio2, Nicolas B Delongchamps3, Cristian Fiori4, Francesco Porpiglia4, Andrea Tubaro2.   

Abstract

INTRODUCTION: Intending to overcome transurethral resection of the prostate (TURP) in terms of safety maintaining its efficacy profile, have led to the introduction of minimally invasive laser therapies to treat men with lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO), each one with its unique properties. The aim of this review was to analyze and summarize all the existing data regarding the 180 W Xcelerated Performance System (XPS) photoselective vaporization of the prostate (PVP). EVIDENCE ACQUISITION: A systematic review was conducted: 45 papers were identified. After excluding those not in English language, duplicates, case reports and "expert opinion" papers, 39 articles were reviewed. EVIDENCE SYNTHESIS: The XPS emits a 532 nm wavelength generated using a lithium triborate crystal in a quasi-continuous mode through a 750 µm, continuously saline-cooled, metal capped MoXy™ fibre. This system has overcome the previous model in terms of surgical and functional outcomes. Although several techniques have been proposed, the IGLU modular one is considered the standard approach for 180 W PVP. Authors estimated the need for at least 120 cases to reach an expert level of competence. The GOLIATH Study has proven the non-inferiority of XPS PVP to TURP. The procedure is safe and effective also in large glands but long operative times still represent an issue. Considering the total average costs, XPS PVP provides and advantage over TURP. International guidelines consider PVP the best option to manage patients receiving anticoagulants or with a high cardiovascular risk.
CONCLUSIONS: PVP should be considered an adult technique and, as suggested by the EAU Guidelines, is the best surgical option to manage patients receiving anticoagulant medication or with a high cardiovascular risk. The development of new surgical techniques such as APV, PEBE and seminal spearing approaches could represent a possibility to further implement the XPS indications. Dedicated unit could improve the management LUTS/BPO men.

Entities:  

Mesh:

Year:  2016        PMID: 27905699     DOI: 10.23736/S0393-2249.16.02791-0

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  5 in total

1.  Comparison of 532-nm GreenLight HPS laser with 980-nm diode laser vaporization of the prostate in treating patients with lower urinary tract symptom secondary to benign prostatic hyperplasia: a meta-analysis.

Authors:  Zhongbao Zhou; Yuanshan Cui; Xiaoyi Zhang; Yong Zhang
Journal:  Lasers Med Sci       Date:  2021-01-28       Impact factor: 3.161

Review 2.  Follow-up of Temporary Implantable Nitinol Device (TIND) Implantation for the Treatment of BPH: a Systematic Review.

Authors:  Riccardo Bertolo; Cristian Fiori; Daniele Amparore; Francesco Porpiglia
Journal:  Curr Urol Rep       Date:  2018-04-26       Impact factor: 3.092

3.  Multicenter experience with photoselective vaporization of the prostate on men taking novel oral anticoagulants.

Authors:  Brooke Sachs; Vincent Misrai; Shahin Tabatabaei; Henry H Woo
Journal:  Asian J Urol       Date:  2019-07-30

4.  Quality of life after photo-selective vaporization and holmium-laser enucleation of the prostate: 5-year outcomes.

Authors:  Inyoung Sun; Sangjun Yoo; Juhyun Park; Sung Yong Cho; Hyeon Jeong; Hwancheol Son; Seung-June Oh; Jae-Seung Paick; Min Chul Cho
Journal:  Sci Rep       Date:  2019-06-04       Impact factor: 4.379

5.  Effects of Psychological Intervention on Perioperative Quality of Life and Serum PSA and FPSA Levels of Patients with Prostate Cancer Treated with Integrated Traditional Chinese and Western Medicine.

Authors:  Xifeng Sun; Yi Lu; Hongxia Zhu; Rui Li; Donghua Zhang; Kunfang Pang
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-26       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.